Top

26-04-2024 | Priapism | Case Report - Complication

Priapism as an initial manifestation in an adult patient with chronic myeloid leukemia in Japan: case report and review of the literature

Authors: Yuya Masuda, Hisaharu Shikata, Hiroshi Sawachika, Masahiko Kaneko

Published in: International Cancer Conference Journal

Abstract

We report the first documented Japanese case in the English literature of chronic myeloid leukemia (CML) in which priapism was the presenting symptom. Priapism, a rare manifestation in CML patients, is particularly uncommon in Japan. This can be attributed to the high quality of medical services and proactive health strategies implemented by the Japanese government. These strategies include recommending regular blood tests for company employees aged 35 and above, thereby facilitating early detection of CML. Hence, it is crucial to consider CML when examining any patient presenting with priapism, particularly among those who have not undergone regular medical check-ups.

Rodgers R, Latif Z, Copland M (2012) How I manage priapism in chronic myeloid leukaemia patients. Br J Haematol 158:155–164. https://doi.org/10.1111/j.1365-2141.2012.09151.xCrossRefPubMed

Earle CM, Stuckey BG, Ching HL et al (2003) The incidence and management of priapism in Western Australia: a 16 year audit. Int J Impot Res 15:272–276. https://doi.org/10.1038/sj.ijir.3901018CrossRefPubMed

Eland IA, van der Lei J, Stricker BH et al (2001) Incidence of priapism in the general population. Urology 57:970–972. https://doi.org/10.1016/s0090-4295(01)00941-4CrossRefPubMed

Roghmann F, Becker A, Sammon JD et al (2013) Incidence of priapism in emergency departments in the United States. J Urol 190:1275–1280. https://doi.org/10.1016/j.juro.2013.03.118CrossRefPubMed

Kulmala RV, Lehtonen TA, Tammela TL (1995) Priapism, its incidence and seasonal distribution in Finland. Scand J Urol Nephrol 29:93–96. https://doi.org/10.3109/00365599509180545CrossRefPubMed

Sugihara T, Yasunaga H, Horiguchi H et al (2011) Incidence and clinical features of priapism in Japan: 46 cases from the Japanese diagnosis procedure combination database 2006–2008. Int J Impot Res 23:76–80. https://doi.org/10.1038/ijir.2011.7CrossRefPubMed

Segawa N, Takasaki N, Iwamoto Y et al (1998) Priapism treated by caverno-glandular shunt, caverno-saphenous shunt and caverno-spongiosum shunt: report of a case (in Japanese). Acta Urologica Japonica 44:297–300PubMed

Nelson JH 3rd, Winter CC (1977) Priapism: evolution of management in 48 patients in a 22-year series. J Urol 117:455–458. https://doi.org/10.1016/s0022-5347(17)58497-9CrossRefPubMed

Jameel T, Mehmood K (2009) Priapism—an unusual presentation in chronic myeloid leukaemia: case report and review of the literature. Biomedica 25:197–199

10.

Chowdhury ZZ, Al-Asad H, Rahman MH et al (2019) Management of priapism with chronic myeloid leukaemia—a rare presentation and our experiences. Haematol J Bangladesh 3:39–41. https://doi.org/10.37545/haematoljbd201941CrossRef

11.

Min Qu, Xin Lu, Wang L et al (2019) Priapism secondary to chronic myeloid leukemia treated by a surgical cavernosa-corpus spongiosum shunt: case report. Asian J Urol 6:373–376. https://doi.org/10.1016/j.ajur.2018.12.004CrossRef

12.

Abd El Salam MA, Ibrahim NH, Hassan S (2019) Discontinuation of treatment in a chronic myeloid leukemia patient caused priapism: a case report. Hum Androl 9:21–23. https://doi.org/10.21608/HA.2019.14398.1045CrossRef

13.

Shaeer OK, Shaeer KZ, AbdelRahman IF et al (2015) Priapism as a result of chronic myeloid leukemia: case report, pathology, and review of the literature. J Sexual Medicine 12:827–834. https://doi.org/10.1111/jsm.12812CrossRef

14.

Dhar J, Chhabra G, Khandelwal L et al (2019) Priapism as a debut presentation of chronic myeloid leukemia. J Coll Physicians Surgeons Pakistan 29:78–80. https://doi.org/10.29271/jcpsp.2019.01.78CrossRef

15.

Afrose R, Nebhnani D, Wadhwa N (2015) Cutaneous myeloid sarcoma of the penile foreskin. Turkish J Pathol 31:131–135. https://doi.org/10.5146/tjpath.2014.01258CrossRef

16.

Jana K, Aggarwal R, Gawande A et al (2013) Priapism: a chronic myeloid leukemia harbinger in exigency. Ann Tropical Medicine Public Health 6:583–585. https://doi.org/10.23750/abm.v92i3.10796CrossRef

17.

Swapna Y, Narmada N (2017) Emergency leukapheresis in chronic myeloid leukemia presenting with priapism. Asian J Pharm Health Sci 7:1701–1704

18.

Dogra PN, Kumar P, Goel R et al (2004) Long duration priapism in blast crisis of chronic myeloid leukemia. J Assoc Physicians India 52:170PubMed

19.

Patil RB, Wasekar N, Bamborde S et al (2019) Priapism: rare presenting manifestation of chronic myeloid leukemia and its management–case series of 5 patients. Int J Science Research 8:35–37

20.

Hazra SP, Priyadarshi V, Gogoi DS et al (2013) Pediatric priapism: a rare first manifestation of leukemia. APSP J Case Reports 4:39

21.

Kumar P, Rahman K, Kumari S et al (2018) Priapism as a rare presentation of chronic myeloid leukemia. J Cancer Res Therapeutics 14:1442–1443. https://doi.org/10.4103/0973-1482.199388CrossRef

22.

Agarwal A, Lavania P (2020) Priapism in a patient of chronic myeloid leukemia: a case report. Indian J Urol 24:S53

23.

Mishra K, Jandial A, Singh V et al (2020) Priapism in chronic myeloid leukemia: meeting at the crossroads and heading in different directions. Indian J Med Paed Oncol 41:418. https://doi.org/10.4103/ijmpo.ijmpo_234_18CrossRef

24.

Shankar J (2011) Priapism in teenager chronic myelogenous leukemia: a rare occurrence. Asian J Pharm Health Sciences 1:226

25.

Gupta A, Seth T, Gupta A (2009) Successful use of terbutaline in persistent priapism in a 12-year-old boy with chronic myeloid leukemia. Pediatr Hematol Oncol 26:70–73. https://doi.org/10.1080/08880010802435146CrossRefPubMed

26.

Nerli RB, Magdum PV, Hiremath SC et al (2016) Priapism—a rare presentation in chronic myeloid leukemia: case report. Urology Case Reports 4:8–10CrossRefPubMed

27.

Castagnetti M, Sainati L, Giona F et al (2008) Conservative management of priapism secondary to leukemia. Pediatr Blood Cancer 51:420–423. https://doi.org/10.1002/pbc.21628CrossRefPubMed

28.

Htun TH, Dublin N, Parameswaran M et al (2008) Chronic myeloid leukaemia presenting as priapism—how should we treat these? J Health Transl Med 11:27–29CrossRef

29.

Huei TJ, Lip HTC, Omar S (2018) A rare presentation of chronic myeloid leukaemia with priapism treated with corporoglandular shunting. Med J Malaysia 73:420–422PubMed

30.

Becerra-Pedraza LC, Jiménez-Martínez LE, Peña-Morfin I et al (2018) Priapism as the initial sign in hematologic disease: case report and literature review. Int J Surg Case Reports 43:13–17. https://doi.org/10.1016/j.ijscr.2017.12.038CrossRef

31.

Irzi M, Mhanna T, El Houmaidi A et al (2020) Delayed penile prosthesis implantation in the delayed presentation of ischemic priapism. Arch Case Reports 4:4–6. https://doi.org/10.29328/journal.acr.1001028CrossRef

32.

Tazi L (2009) Priapism as the first manifestation of chronic myeloid leukemia. Ann Saudi Medicine 29:412. https://doi.org/10.4103/0256-4947.55176CrossRef

33.

Ocheni S, Ibegbulam O, Olusina D et al (2010) Chronic myeloid leukaemia presenting as priapism: a report of 2 cases and review of literature. Int J Medicine and Health Development 15:76–81

34.

Ekeke O, Omunakwe H, Nwauche C (2015) Chronic myeloid leukaemia presenting as priapism. Int Surg 100:552–557CrossRefPubMedPubMedCentral

35.

Ocheni S, Ibegbulam O, Olusina D et al (2012) Chronic myeloid leukaemia presenting as priapism: a report of 2 cases and review of literature. J Clinical Medicine 15:76–81

36.

Khan A, Shafiq I, Shah MH et al (2018) Chronic myeloid leukaemia presenting as priapism: a case report from khyber pakhtunkhwa. J Pak Med Assoc 68:942–944PubMed

37.

Ervie M, Boongaling DC, Rose S et al (2015) Priapism as a rare presentation of chronic myelogenous leukemia. Philippine J Internal Medicine 53:1–5

38.

Almaeena W, Azzuz S (2020) Undiagnosed chronic myelogenous leukemia presented by priapism. Int J Science Academic Research 4:20–21

39.

Farhan S, Anjum F, Al-Qahtani FS et al (2014) Chronic myeloid leukemia presenting with priapism. J Leukemia 3:171. https://doi.org/10.4172/2329-6917.1000171CrossRef

40.

Veljković D, Kuzmanović M, Mićić D et al (2012) Leukapheresis in management hyperleucocytosis induced complications in two pediatric patients with chronic myelogenous leukemia. Transfus Apher Sci 46:263–267. https://doi.org/10.1016/j.transci.2012.03.012CrossRefPubMed

41.

Villegas Osorio JF, Corchuelo Maíllo C, Cuevas Palomino A et al (2014) Ischaemic priapism as a presentation of chronic myeloid leukaemia. Arch Esp Urol 67:708–711PubMed

42.

Chang M-W, Tang C-C, Chang SS (2003) Priapism—a rare presentation in chronic myeloid leukemia: case report and review of the literature. Chang Gung Med J 26:288–292PubMed

43.

Avci AE, Kurtulus F, Fazlioglu A et al (2005) Priapism as an initial presentation of chronic myelogenous leukemia: a case report. Uluslarar Hematol-Onkol Derg 15:153–155

44.

Ergenc H, Varım C, Karacaer C et al (2015) Chronic myeloid leukemia presented with priapism: effective management with prompt leukapheresis. Niger J Clin Pract 18:828–830. https://doi.org/10.4103/1119-3077.163282CrossRefPubMed

45.

Ponniah A, Brown CT, Taylor P (2004) Priapism secondary to leukemia: effective management with prompt leukapheresis. Int J Urol 11:809–810. https://doi.org/10.1111/j.1442-2042.2004.00872.xCrossRefPubMed

46.

Shafique S, Bona R, Kaplan AA (2007) A case report of therapeutic leukapheresis in an adult with chronic myelogenous leukemia presenting with hyperleukocytosis and leukostasis. Ther Apher Dial 11:146–149. https://doi.org/10.1111/j.1744-9987.2007.00417.xCrossRefPubMed

47.

Clark AJ, Hsu P, Darves-Bornoz A et al (2018) Priapism in a 13-year-old boy. Pediatr Rev 39:617–619. https://doi.org/10.1542/pir.2017-0051CrossRefPubMed

48.

Abbott LS, Moineau G, Johnston DL (2008) Case 1: an unusual cause of headaches and priapism in a teenager. Paediatr Child Health 13:299–301. https://doi.org/10.1093/pch/13.4.299CrossRefPubMedPubMedCentral

49.

Sun HH, Zhang JH, DeWitt-Foy M et al (2019) Urologic management of priapism secondary to chronic myeloid leukemia. Urology 125:24–28. https://doi.org/10.1016/j.urology.2018.11.021CrossRefPubMed

50.

Minckler MR, Conser E, Figueroa JJ et al (2017) The semantics of priapism and the first sign of chronic myeloid leukemia. Case Rep Emerg Med 2017:2656203. https://doi.org/10.1155/2017/2656203CrossRefPubMedPubMedCentral

51.

Access GBDH, Quality Collaborators. Electronic address cue, Access GBDH (2017) Healthcare access and quality index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990–2015: a novel analysis from the global burden of disease study 2015. Lancet 390:231–266. https://doi.org/10.1016/S0140-6736(17)30818-8CrossRef

52.

Malhotra H, Radich J, Garcia-Gonzalez P (2019) Meeting the needs of CML patients in resource–poor countries. Hematology Am Soc Hematol Educ Program 2019(1):433–442. https://doi.org/10.1182/hematology.2019000050CrossRefPubMedPubMedCentral

53.

Ali E, Soliman A, De Sanctis V et al (2021) Priapism in patients with chronic myeloid leukemia (CML): a systematic review. Acta Biomed 92(3):e2021193. https://doi.org/10.23750/abm.v92i3.10796CrossRefPubMedPubMedCentral

54.

Kuwabara Y, Fujii M, Kinjo A et al (2022) (2022) Abstaining from annual health check-ups is a predictor of advanced cancer diagnosis: a retrospective cohort study. Environ Health Prev Med 27:1. https://doi.org/10.1265/ehpm.21-00292CrossRefPubMedPubMedCentral

Title: Priapism as an initial manifestation in an adult patient with chronic myeloid leukemia in Japan: case report and review of the literature
Authors: Yuya Masuda
Hisaharu Shikata
Hiroshi Sawachika
Masahiko Kaneko
Publication date: 26-04-2024
Publisher: Springer Nature Singapore
Keywords: Priapism
Chronic Myeloid Leukemia
Imatinib
Published in: International Cancer Conference Journal
Electronic ISSN: 2192-3183
DOI: https://doi.org/10.1007/s13691-024-00680-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Please log in to get access to this content

Keynote webinar | Spotlight on antibody–drug conjugates in cancer